According to him, this would make it easier, cheaper and faster to conduct clinical trials with psilocybin. He also cited the drug's 'exciting' potential to treat a range of mental illnesses, including depression, trauma and addiction.Д«lunt, who is also the president of the Conservative Drug Policy Reform Group, a policy forum which promotes informed debate on drug policy reform, asked, 'Will end the current barriers to research on psilocybin and similar compounds for the British public to receive, and British scientific research and British scientific companies to allow potential treatments in these most debilitating conditions to be delivered as soon as possible?'Д«oris Johnson replied, 'I can tell him that we will consider the recent advice from the Advisory Council on the Misuse of Drugs on reducing barriers to controlled drug research such as the one he describes, and we will get back to him as soon as possible.'ДЄs chairman of the Conservative Drug Policy Reform Group, Blunt has repeatedly called on the government to urgently re-schedule psilocybin in Schedule 2 of the Misuse of Drugs Act. Johnson to review the classification of psilocybin as a Schedule 1 drug. During Prime Minister's Question Time, Conservative MP and drug reform advocate Crispin Blunt asked Mr.

Tradestation forum